Zacks Investment Research upgraded shares of KemPharm Inc (NASDAQ:KMPH) from a hold rating to a buy rating in a research report report published on Tuesday. They currently have $4.75 price objective on the specialty pharmaceutical company’s stock.

According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “

KMPH has been the topic of a number of other reports. Canaccord Genuity set a $7.00 price objective on shares of KemPharm and gave the company a buy rating in a research note on Sunday, March 12th. Oppenheimer Holdings Inc. set a $13.00 price objective on shares of KemPharm and gave the company a buy rating in a research note on Saturday, March 11th. Finally, Royal Bank of Canada reiterated an outperform rating and set a $8.00 price objective on shares of KemPharm in a research note on Saturday, March 11th.

KemPharm (NASDAQ:KMPH) traded down 1.036% during midday trading on Tuesday, reaching $4.107. 5,729 shares of the company’s stock were exchanged. KemPharm has a 12-month low of $2.90 and a 12-month high of $19.75. The stock’s market capitalization is $60.15 million. The stock’s 50-day moving average is $3.83 and its 200-day moving average is $3.91.

KemPharm (NASDAQ:KMPH) last issued its earnings results on Thursday, March 9th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.02. On average, equities analysts forecast that KemPharm will post ($2.53) earnings per share for the current year.

Your IP Address:

Several institutional investors have recently added to or reduced their stakes in KMPH. Alyeska Investment Group L.P. increased its position in KemPharm by 3.2% in the fourth quarter. Alyeska Investment Group L.P. now owns 998,742 shares of the specialty pharmaceutical company’s stock worth $2,946,000 after buying an additional 31,415 shares in the last quarter. Arete Wealth Advisors LLC increased its position in KemPharm by 0.8% in the third quarter. Arete Wealth Advisors LLC now owns 834,602 shares of the specialty pharmaceutical company’s stock worth $3,747,000 after buying an additional 6,857 shares in the last quarter. Parkwood LLC increased its position in KemPharm by 369.3% in the third quarter. Parkwood LLC now owns 125,809 shares of the specialty pharmaceutical company’s stock worth $565,000 after buying an additional 99,000 shares in the last quarter. Creative Planning increased its position in KemPharm by 4,571.3% in the third quarter. Creative Planning now owns 410,794 shares of the specialty pharmaceutical company’s stock worth $1,844,000 after buying an additional 402,000 shares in the last quarter. Finally, DSC Advisors L.P. increased its position in KemPharm by 54.7% in the fourth quarter. DSC Advisors L.P. now owns 1,459,193 shares of the specialty pharmaceutical company’s stock worth $4,305,000 after buying an additional 515,708 shares in the last quarter. Hedge funds and other institutional investors own 44.36% of the company’s stock.

About KemPharm

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

5 Day Chart for NASDAQ:KMPH

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KemPharm Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc and related companies with MarketBeat.com's FREE daily email newsletter.